NeoDynamics Receives 1st UK Order of Pulse Biopsy System NeoNavia: Product Demos Generating Significant Interest

November 19, 2020

NeoDynamics AB, advancing diagnosis and care of breast cancer, announces today that the Company has received the first UK order from the Buckinghamshire Healthcare NHS Trust, London, of its pulse biopsy system, NeoNavia.

NeoDynamics AB (is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden.

NeoDynamics reports product demonstrations at several centers have gained significant interest, and the company has now received the first commercial order of its pulse biopsy system including three needle options for all ultrasound led biopsy procedures. The UK team of NeoDynamics has managed to introduce physicians at key centers to the new pulse biopsy system, despite the difficulties in accessing hospitals and key staff following the pandemic.

“The first order of NeoNavia from a London based Hospital Trust is an important milestone for NeoDynamics, and we will be working closely with the centre to ensure a timely delivery and successful use. The consolidated feedback from the physicians who have participated in hands-on workshops, is very positive. Our long-term goal by introducing the pioneering pulse biopsy technology for ultrasound guided biopsy in breast and axilla is to advance the way biopsies are taken and ultimately improve patient outcomes. Over time, we believe that the versatile pulse biopsy system could transform standard practice”, says Ian Galloway, Country Manager UK & Ireland, Neodynamics.

Breast cancer is the most common cancer among women in the UK. With around 55,000 cases, it represented 15% of all new cancer cases in 2017. It is critical that new biopsy technologies can offer a controlled way for lesion targeting as well as accurate and reliable diagnosis through high quality tissue samples.

The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type, size and location. The pneumatic driver that generates the pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.

Exit mobile version